3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Sexual Dysfunction, Physiological
1
Interventions
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
10
human papillomavirus vaccine, L1 type 16, 18
7
olaparib
4
niraparib
4
Human Papillomavirus Recombinant Vaccine nonavalent
4
Vaccines
3
Saline Solution
3
Papillomavirus Vaccines
3
Medroxyprogesterone Acetate
3
Carboplatin
3
Bevacizumab
3
pegylated granulocyte colony-stimulating factor
2
liposomal doxorubicin
2
fluciclovine F-18
2
apatinib
2
Sevoflurane
2
Propofol
2
Paclitaxel
2
Aspirin
2
semaglutide
1
pegfilgrastim
1
pazopanib
1
palbociclib
1
lenvatinib
1
halofantrine
1
ganirelix
1
gadofosveset trisodium
1
fosaprepitant
1
follicle stimulating hormone, human, with HCG C-terminal peptide
1
ferrous gluconate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Quality of Life
×
Gynecologic
×
Clear all
NCT06031493
2024-02-28
PROVIDENCE
Hospital Clinic of Barcelona
Phase 4
Unknown
122 enrolled